CNTRP POSITIVE Study
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- The Hospital for Sick Children
- Principal Investigator
- Seema Mital, MDSickKids Hospital
- Enrollment
- 600 enrolled
- Eligibility
- 0-25 years · All sexes
- Timeline
- 2014 – 2020
Study locations (1)
- SickKids Hospital, Toronto, Ontario, Canada
Collaborators
Canadian Institutes of Health Research (CIHR) · Alberta Children's Hospital · Stollery Children's Hospital · St. Justine's Hospital · The Children's Hospital of Winnipeg · Montreal Children's Hospital of the MUHC · Provincial Health Services Authority British Columbia · Toronto General Hospital · Vancouver General Hospital · Royal Victoria Hospital, Canada · The Ottawa Hospital · Foothills Medical Centre · Centre hospitalier de l'Université de Montréal (CHUM) · University of British Columbia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02318030 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07389616A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07470996T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NRShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06483100Measurable Residual Disease-Guided Post-Transplant Elranatamab MaintenanceWashington University School of Medicine
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
See all trials for Post-transplant lymphoproliferative disease →